RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

Nature - Tập 480 Số 7377 - Trang 387-390 - 2011
Poulikos I. Poulikakos1, Yogindra Persaud2, Manickam Janakiraman2, Xiangju Kong3, Charles Ng4, Gatien Moriceau3, Hubing Shi3, Mohammad Atefi4, Bjoern Titz5, May Tal Gabay1, Maayan Salton6, Kimberly B. Dahlman7, Madhavi Tadi1, Jennifer A. Wargo8, Keith T. Flaherty9, Mark C. Kelley10, Tom Misteli6, Paul B. Chapman11, Jeffrey A. Sosman7, Thomas G. Graeber5, Antoni Ribas5, Roger S. Lo5, Neal Rosen11, David B. Solit11
1Department of Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, New York, 10065, New York, USA
2Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, 10065, New York, USA
3Division of Dermatology, Department of Medicine, Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, 90095, California, USA
4Division of Hematology and Oncology, Department of Medicine, Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, 90095, California, USA
5Department of Molecular and Medical Pharmacology, Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, 90095, California, USA
6National Cancer Institute, NIH, Bethesda, 20892, Maryland, USA
7Department of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, 37232, Tennessee, USA
8Department of Surgery, Massachusetts General Hospital Cancer Center, Boston, 02114, Massachusetts, USA
9Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, 02114, Massachusetts, USA
10Department of Surgery, Vanderbilt-Ingram Cancer Center, Nashville, 37232, Tennessee, USA
11Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, 10065, New York, USA

Tóm tắt

Từ khóa


Tài liệu tham khảo

Weber, C. K., Slupsky, J. R., Kalmes, H. A. & Rapp, U. R. Active Ras induces heterodimerization of cRaf and BRaf. Cancer Res. 61, 3595–3598 (2001)

Rushworth, L. K., Hindley, A. D., O’Neill, E. & Kolch, W. Regulation and role of Raf-1/B-Raf heterodimerization. Mol. Cell Biol. 26, 2262–2272 (2006)

Wellbrock, C., Karasarides, M. & Marais, R. The RAF proteins take centre stage. Nature Rev. Mol. Cell Biol. 5, 875–885 (2004)

Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M. & Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427–430 (2010)

Heidorn, S. J. et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209–221 (2010)

Hatzivassiliou, G. et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431–435 (2010)

Joseph, E. W. et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc. Natl Acad. Sci. USA 107, 14903–14908 (2010)

Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809–819 (2010)

Solit, D. B. et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358–362 (2006)

Whittaker, S. et al. Gatekeeper mutations mediate resistance to BRAF-targeted therapies. Sci. Transl. Med. 2, 35ra41 (2010)

Cutler, R. E., Jr, Stephens, R. M., Saracino, M. R. & Morrison, D. K. Autoregulation of the Raf-1 serine/threonine kinase. Proc. Natl Acad. Sci. USA 95, 9214–9219 (1998)

Rajakulendran, T., Sahmi, M., Lefrancois, M., Sicheri, F. & Therrien, M. A dimerization-dependent mechanism drives RAF catalytic activation. Nature 461, 542–545 (2009)

Poulikakos, P. I. & Rosen, N. Mutant BRAF melanomas–dependence and resistance. Cancer Cell 19, 11–15 (2011)

McArthur, G. et al. Molecular analyses from a phase I trial of vemurafenib to study mechanism of action (MOA) and resistance in repeated biopsies from BRAF mutation–positive metastatic melanoma patients (pts). J Clin Oncol 29, suppl; abstr 8502. (2011)

Nazarian, R. et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973–977 (2010)

Johannessen, C. M. et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968–972 (2010)

Villanueva, J. et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18 683–695 S1535–6108(10)00484–8 (2010)

Wagle, N. et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. 29, 3085–3096 (2011)

Luco, R. F., Allo, M., Schor, I. E., Kornblihtt, A. R. & Misteli, T. Epigenetics in alternative pre-mRNA splicing. Cell 144, 16–26 (2011)

Bollag, G. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596–599 (2010)

Janakiraman, M. et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 70, 5901–5911 (2010)

Nüsse, M., Beisker, W., Hoffmann, C. & Tarnok, A. Flow cytometric analysis of G1- and G2/M-phase subpopulations in mammalian cell nuclei using side scatter and DNA content measurements. Cytometry 11, 813–821 (1990)

Thông tin
Thông tin xuất bản

Nature

Tập 480 Số 7377

387-390

Thông tin tác giả